# US 2022/0031775 A1 · Probiotic composition and method for improving an effect of chemotherapeutic drug of gemcitabine on inhibiting pancreatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031775 A1
- Document ID: US20220031775A1
- Status: Published application
- Kind: A1
- Application number: 17/317,928
- Filed: 2021-05-12
- Published: 2022-02-03
- Earliest claimed: 2020-07-29
- Assignees: GenMont Biotech Inc.
- Applicants: Genmont Biotech Inc.
- Inventors: Wan-Hua TSAI; I-ling HSU; Shan-ju HSU; Wen-ling YEH; Ming-shiou JAN; Wee-wei CHIENG; Li-jin HSU; Ying-chun LAI
- Web page: https://patentgrep.com/patent/US20220031775A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

## Claims

### Claim 1

A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer, comprising: an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154.

### Claim 2 (depends on 1)

The probiotic composition of claim 1, wherein a ratio of a number of bacteria of the Lactobacillus paracasei GMNL-133 to a number of bacteria of the Lactobacillus reuteri GMNL-89 ranges from 1:0.1 to 1:1.

### Claim 3 (depends on 1)

A method for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer, comprising a step of administering the probiotic composition of claim 1 to a subject in need.

### Claim 4 (depends on 3)

The method of claim 3, wherein a ratio of a number of bacteria of the Lactobacillus paracasei GMNL-133 to a number of bacteria of the Lactobacillus reuteri GMNL-89 ranges from 1:0.1 to 1:1.

### Claim 5 (depends on 3)

The method of claim 3, wherein the Lactobacillus paracasei GMNL-133 in the probiotic composition is administered at a dose of 4×109 to 4×1010 cfu/60 kg of body weight per day to a subject in need of improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer, and the Lactobacillus reuteri GMNL-89 in the probiotic composition is administered at a dose of 4×109 to 4×1010 cfu/60 kg of body weight per day to the subject in need of improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer.

### Claim 6 (depends on 3)

The method of claim 3, wherein the Lactobacillus paracasei GMNL-133 in the probiotic composition is administered at a dose of 4×109 to 4×1010 cfu/60 kg of body weight per day to a subject in need of improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer, and the Lactobacillus reuteri GMNL-89 in the probiotic composition is administered at a dose of 4×108 to 4×109 cfu/60 kg of body weight per day to the subject in need of improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer.

### Claim 7 (depends on 1)

A method for improving a side effect of a chemotherapeutic drug of Gemcitabine, comprising a step of administering the probiotic composition of claim 1 to a subject in need.

### Claim 8 (depends on 7)

The method of claim 7, wherein a ratio of a number of bacteria of the Lactobacillus paracasei GMNL-133 to a number of bacteria of the Lactobacillus reuteri GMNL-89 ranges from 1:0.1 to 1:1.

### Claim 9 (depends on 7)

The method of claim 7, wherein the Lactobacillus paracasei GMNL-133 in the probiotic composition is administered at a dose of 4×109 to 4×1010 cfu/60 kg of body weight per day to a subject in need of improving the side effect of the chemotherapeutic drug of Gemcitabine, and the Lactobacillus reuteri GMNL-89 in the probiotic composition is administered at a dose of 4×109 to 4×1010 cfu/60 kg of body weight per day to the subject in need of improving the side effect of the chemotherapeutic drug of Gemcitabine.

### Claim 10 (depends on 7)

The method of claim 7, wherein the Lactobacillus paracasei GMNL-133 in the probiotic composition is administered at a dose of 4×109 to 4×1010 cfu/60 kg of body weight per day to a subject in need of improving the side effect of the chemotherapeutic drug of Gemcitabine, and the Lactobacillus reuteri GMNL-89 in the probiotic composition is administered at a dose of 4×108 to 4×109 cfu/60 kg of body weight per day to the subject in need of improving the side effect of the chemotherapeutic drug of Gemcitabine.
